Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: A preliminary open label study

Michele Fornaro, Michael J. McCarthy, Domenico De Berardis, Concetta De Pasquale, Massimo Tabaton, Matteo Martino, Salvatore Colicchio, Carlo Ignazio Cattaneo, Emanuela D'Angelo, Pantaleo Fornaro

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose: The circadian rhythm hypothesis of bipolar disorder (BD) suggests a role for melatonin in regulating mood, thus extending the interest toward the melatonergic antidepressant agomelatine as well as type I (acute) or II cases of bipolar depression. Patients and methods: Twenty-eight depressed BD-II patients received open label agomelatine (25 mg/bedtime) for 6 consecutive weeks as an adjunct to treatment with lithium or valproate, followed by an optional treatment extension of 30 weeks. Measures included the Hamilton depression scale, Pittsburgh Sleep Quality Index, the Clinical Global Impression Scale-Bipolar Version, Young Mania Rating Scale, and body mass index. Results: Intent to treat analysis results demonstrated that 18 of the 28 subjects (64%) showed medication response after 6 weeks (primary study endpoint), while 24 of the 28 subjects (86%) responded by 36 weeks. When examining primary mood stabilizer treatment, 12 of the 17 (70.6%) valproate and six of the 11 (54.5%) lithium patients responded by the frst endpoint. At 36 weeks, 14 valproate treated (82.4%) and 10 lithium treated (90.9%) subjects responded. At 36 weeks, there was a slight yet statistically signifcant (P = 0.001) reduction in body mass index and Pittsburgh Sleep Quality Index scores compared to respective baseline values, regardless of mood stabilizer/outcome. Treatment related drop-out cases included four patients (14.28%) at week 6 two valproate-treated subjects with pseudo-vertigo and drug-induced hypomania, respectively, and two lithium-treated subjects with insomnia and mania, respectively. Week 36 drop outs were two hypomanic cases, one per group. Conclusion: Agomelatine 25 mg/day was an effective and well-tolerated adjunct to valproate/ lithium for acute depression in BD-II, suggesting the need for confrmation by future double blind, controlled clinical trials.

Original languageEnglish
Pages (from-to)243-251
Number of pages9
JournalNeuropsychiatric Disease and Treatment
Volume9
DOIs
Publication statusPublished - Feb 14 2013
Externally publishedYes

Fingerprint

S 20098
Bipolar Disorder
Valproic Acid
Lithium
Sleep
Body Mass Index
Therapeutics
Depression
Vertigo
Controlled Clinical Trials
Sleep Initiation and Maintenance Disorders
Melatonin
Circadian Rhythm
Antidepressive Agents

Keywords

  • Acute bipolar depression
  • Adjunctive treatment
  • Agomelatine
  • Bipolar disorder type-II

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Adjunctive agomelatine therapy in the treatment of acute bipolar II depression : A preliminary open label study. / Fornaro, Michele; McCarthy, Michael J.; De Berardis, Domenico; De Pasquale, Concetta; Tabaton, Massimo; Martino, Matteo; Colicchio, Salvatore; Cattaneo, Carlo Ignazio; D'Angelo, Emanuela; Fornaro, Pantaleo.

In: Neuropsychiatric Disease and Treatment, Vol. 9, 14.02.2013, p. 243-251.

Research output: Contribution to journalArticle

Fornaro, M, McCarthy, MJ, De Berardis, D, De Pasquale, C, Tabaton, M, Martino, M, Colicchio, S, Cattaneo, CI, D'Angelo, E & Fornaro, P 2013, 'Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: A preliminary open label study', Neuropsychiatric Disease and Treatment, vol. 9, pp. 243-251. https://doi.org/10.2147/NDT.S41557
Fornaro, Michele ; McCarthy, Michael J. ; De Berardis, Domenico ; De Pasquale, Concetta ; Tabaton, Massimo ; Martino, Matteo ; Colicchio, Salvatore ; Cattaneo, Carlo Ignazio ; D'Angelo, Emanuela ; Fornaro, Pantaleo. / Adjunctive agomelatine therapy in the treatment of acute bipolar II depression : A preliminary open label study. In: Neuropsychiatric Disease and Treatment. 2013 ; Vol. 9. pp. 243-251.
@article{350cfb82099d4be9b0a41ebf3fb84499,
title = "Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: A preliminary open label study",
abstract = "Purpose: The circadian rhythm hypothesis of bipolar disorder (BD) suggests a role for melatonin in regulating mood, thus extending the interest toward the melatonergic antidepressant agomelatine as well as type I (acute) or II cases of bipolar depression. Patients and methods: Twenty-eight depressed BD-II patients received open label agomelatine (25 mg/bedtime) for 6 consecutive weeks as an adjunct to treatment with lithium or valproate, followed by an optional treatment extension of 30 weeks. Measures included the Hamilton depression scale, Pittsburgh Sleep Quality Index, the Clinical Global Impression Scale-Bipolar Version, Young Mania Rating Scale, and body mass index. Results: Intent to treat analysis results demonstrated that 18 of the 28 subjects (64{\%}) showed medication response after 6 weeks (primary study endpoint), while 24 of the 28 subjects (86{\%}) responded by 36 weeks. When examining primary mood stabilizer treatment, 12 of the 17 (70.6{\%}) valproate and six of the 11 (54.5{\%}) lithium patients responded by the frst endpoint. At 36 weeks, 14 valproate treated (82.4{\%}) and 10 lithium treated (90.9{\%}) subjects responded. At 36 weeks, there was a slight yet statistically signifcant (P = 0.001) reduction in body mass index and Pittsburgh Sleep Quality Index scores compared to respective baseline values, regardless of mood stabilizer/outcome. Treatment related drop-out cases included four patients (14.28{\%}) at week 6 two valproate-treated subjects with pseudo-vertigo and drug-induced hypomania, respectively, and two lithium-treated subjects with insomnia and mania, respectively. Week 36 drop outs were two hypomanic cases, one per group. Conclusion: Agomelatine 25 mg/day was an effective and well-tolerated adjunct to valproate/ lithium for acute depression in BD-II, suggesting the need for confrmation by future double blind, controlled clinical trials.",
keywords = "Acute bipolar depression, Adjunctive treatment, Agomelatine, Bipolar disorder type-II",
author = "Michele Fornaro and McCarthy, {Michael J.} and {De Berardis}, Domenico and {De Pasquale}, Concetta and Massimo Tabaton and Matteo Martino and Salvatore Colicchio and Cattaneo, {Carlo Ignazio} and Emanuela D'Angelo and Pantaleo Fornaro",
year = "2013",
month = "2",
day = "14",
doi = "10.2147/NDT.S41557",
language = "English",
volume = "9",
pages = "243--251",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Adjunctive agomelatine therapy in the treatment of acute bipolar II depression

T2 - A preliminary open label study

AU - Fornaro, Michele

AU - McCarthy, Michael J.

AU - De Berardis, Domenico

AU - De Pasquale, Concetta

AU - Tabaton, Massimo

AU - Martino, Matteo

AU - Colicchio, Salvatore

AU - Cattaneo, Carlo Ignazio

AU - D'Angelo, Emanuela

AU - Fornaro, Pantaleo

PY - 2013/2/14

Y1 - 2013/2/14

N2 - Purpose: The circadian rhythm hypothesis of bipolar disorder (BD) suggests a role for melatonin in regulating mood, thus extending the interest toward the melatonergic antidepressant agomelatine as well as type I (acute) or II cases of bipolar depression. Patients and methods: Twenty-eight depressed BD-II patients received open label agomelatine (25 mg/bedtime) for 6 consecutive weeks as an adjunct to treatment with lithium or valproate, followed by an optional treatment extension of 30 weeks. Measures included the Hamilton depression scale, Pittsburgh Sleep Quality Index, the Clinical Global Impression Scale-Bipolar Version, Young Mania Rating Scale, and body mass index. Results: Intent to treat analysis results demonstrated that 18 of the 28 subjects (64%) showed medication response after 6 weeks (primary study endpoint), while 24 of the 28 subjects (86%) responded by 36 weeks. When examining primary mood stabilizer treatment, 12 of the 17 (70.6%) valproate and six of the 11 (54.5%) lithium patients responded by the frst endpoint. At 36 weeks, 14 valproate treated (82.4%) and 10 lithium treated (90.9%) subjects responded. At 36 weeks, there was a slight yet statistically signifcant (P = 0.001) reduction in body mass index and Pittsburgh Sleep Quality Index scores compared to respective baseline values, regardless of mood stabilizer/outcome. Treatment related drop-out cases included four patients (14.28%) at week 6 two valproate-treated subjects with pseudo-vertigo and drug-induced hypomania, respectively, and two lithium-treated subjects with insomnia and mania, respectively. Week 36 drop outs were two hypomanic cases, one per group. Conclusion: Agomelatine 25 mg/day was an effective and well-tolerated adjunct to valproate/ lithium for acute depression in BD-II, suggesting the need for confrmation by future double blind, controlled clinical trials.

AB - Purpose: The circadian rhythm hypothesis of bipolar disorder (BD) suggests a role for melatonin in regulating mood, thus extending the interest toward the melatonergic antidepressant agomelatine as well as type I (acute) or II cases of bipolar depression. Patients and methods: Twenty-eight depressed BD-II patients received open label agomelatine (25 mg/bedtime) for 6 consecutive weeks as an adjunct to treatment with lithium or valproate, followed by an optional treatment extension of 30 weeks. Measures included the Hamilton depression scale, Pittsburgh Sleep Quality Index, the Clinical Global Impression Scale-Bipolar Version, Young Mania Rating Scale, and body mass index. Results: Intent to treat analysis results demonstrated that 18 of the 28 subjects (64%) showed medication response after 6 weeks (primary study endpoint), while 24 of the 28 subjects (86%) responded by 36 weeks. When examining primary mood stabilizer treatment, 12 of the 17 (70.6%) valproate and six of the 11 (54.5%) lithium patients responded by the frst endpoint. At 36 weeks, 14 valproate treated (82.4%) and 10 lithium treated (90.9%) subjects responded. At 36 weeks, there was a slight yet statistically signifcant (P = 0.001) reduction in body mass index and Pittsburgh Sleep Quality Index scores compared to respective baseline values, regardless of mood stabilizer/outcome. Treatment related drop-out cases included four patients (14.28%) at week 6 two valproate-treated subjects with pseudo-vertigo and drug-induced hypomania, respectively, and two lithium-treated subjects with insomnia and mania, respectively. Week 36 drop outs were two hypomanic cases, one per group. Conclusion: Agomelatine 25 mg/day was an effective and well-tolerated adjunct to valproate/ lithium for acute depression in BD-II, suggesting the need for confrmation by future double blind, controlled clinical trials.

KW - Acute bipolar depression

KW - Adjunctive treatment

KW - Agomelatine

KW - Bipolar disorder type-II

UR - http://www.scopus.com/inward/record.url?scp=84874348277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874348277&partnerID=8YFLogxK

U2 - 10.2147/NDT.S41557

DO - 10.2147/NDT.S41557

M3 - Article

AN - SCOPUS:84874348277

VL - 9

SP - 243

EP - 251

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -